An open-label trial of OROS methylphenidate in adults with late-onset ADHD

CNS Spectrums
Joseph BiedermanKarl Schweitzer

Abstract

Many adults with current impairing symptoms of attention-deficit/hyperactivity disorder (ADHD) do not report an age at onset before 7 years of age and cannot, therefore, be assigned the full Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), diagnosis of ADHD. We hypothesized that treatment with oral release osmotic system (OROS) methylphenidate (MPH) will be safe and efficacious for the treatment of adults with late-onset ADHD. This was a 6-week, open-label, prospective treatment study of OROS MPH monotherapy in 36 adult patients with late-onset ADHD (onset later than the required 7 years of age) using standardized instruments for diagnosis and a robust oral daily dose of up to 1.3 mg/kg/day. Symptom severity was assessed with the Adult ADHD Investigator Symptom Report Scale (AISRS) and the Clinical Global Impression (CGI) scale. Subjects reported robust current symptoms of ADHD at pre-treatment baseline (11.1+/-2.8 DSM-IV symptoms), but had an atypical mean age at onset of 14.2+/-8.6 years. Treatment with OROS MPH at an average daily dose of 78.2+/-29.4 mg was associated with a statistically and clinically significant reduction in ADHD symptoms relative to baseline as assessed through the AISRS (-...Continue Reading

References

Dec 1, 1976·Archives of General Psychiatry·D R WoodG E Johnson
Jan 1, 1985·Clinical Neuropharmacology·C T GualtieriC Finley
Nov 1, 1984·Archives of General Psychiatry·J A MattesH Oliver
Oct 25, 2003·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·Rachelle BouffardFiorella Iaboni-Kassab
Mar 25, 2004·Biological Psychiatry·Joseph BiedermanElizabeth Cadogen
Apr 6, 2004·The Psychiatric Clinics of North America·Stephen V Faraone
Apr 6, 2004·The Psychiatric Clinics of North America·Larry J SeidmanGeorge Bush

❮ Previous
Next ❯

Citations

Jan 1, 2010·Journal of Central Nervous System Disease·Michael A SopkoBenjamin Chavez
Sep 13, 2017·Journal of Attention Disorders·Yu-Ju Lin, Susan Shur-Fen Gau
Apr 10, 2018·Journal of Attention Disorders·Mary V Solanto
May 27, 2016·The Cochrane Database of Systematic Reviews·Tamir EpsteinMark Weiser
Jun 21, 2008·CNS Spectrums·Timothy E Wilens
Oct 2, 2009·Journal of Attention Disorders·Thomas J SpencerDouglas K Kelsey
May 17, 2012·Attention Deficit and Hyperactivity Disorders·Breno MatteEugenio Horácio Grevet
Oct 15, 2019·The World Journal of Biological Psychiatry : the Official Journal of the World Federation of Societies of Biological Psychiatry·Gagan JoshiJoseph Biederman
Oct 6, 2006·Expert Opinion on Pharmacotherapy·David Coghill, Sarah Seth
Aug 14, 2009·Expert Review of Neurotherapeutics·J Antoni Ramos-QuirogaMiguel Casas
Oct 30, 2008·Current Neurology and Neuroscience Reports·Paul HammernessKatherine Miller

❮ Previous
Next ❯

Related Concepts

Related Feeds

Attention Disorders

Attention is involved in all cognitive activities, and attention disorders are reported in patients with various neurological diseases. Here are the latest discoveries pertaining to attention disorders.